inclusion criteria: 1. adults of 18 years of age, and older. 2. confirmed hiv infection * at least two hiv plasma viral load (pvl) below 40 copies in the last 12 months, one within the last 60 days (value obtained at screening visit can be used for the value within the last 60 days) * a cd4 count at screening equal or above 300 cells/ml and a cd4 percentage equal or above 15 % within the previous 60 days (value obtained at screening visit can be used for the value within the last 60 days) * participant must be on a stable highly active anti-retroviral treatment (haart) for 6 months (unless the change is due to tolerability, in which case the regimen can be for only the previous 3 months) and with an estimated adherence of ≥80% within the last 60 days. - a haart regimen (as defined by the argentinean art guidelines), means a combination of 2 nrtis plus one insti or a nnrti or a boosted pi or a dual combination of dolutegravir and 3tc. 3. able and willing (in the investigator's opinion) to comply with all study requirements. 4. willing to allow the investigators to discuss the volunteer's medical history with their general practitioner/personal doctor and access all medical records when relevant to study procedures. 5. healthy adults, or stable-healthy adults who may have a pre-existing medical condition that does not meet any exclusion criteria. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment. 6. for females of childbearing potential only, willingness to practice continuous effective contraception (see glossary) for 30 days prior to enrollment in the study, for 90 days after receiving vaccination during the study, and have a negative pregnancy test on the day(s) of screening/ vaccination (first injection visit and second injection visit). 7. males participating in this study who are involved in heterosexual sexual activity must agree to practice adequate contraception (see glossary) and refrain from donating sperm for 90 days after receiving the study vaccination. 8. agreement to refrain from blood donation during the study. 9. provide written informed consent.

inclusion criteria: 1. adults of 18 years of age, and older. 2. confirmed hiv infection * at least two hiv plasma viral load (pvl) below 40 copies in the last 12 months, one within the last 60 days (value obtained at screening visit can be used for the value within the last 60 days) * a cd4 count at screening equal or above 300 cells/ml and a cd4 percentage equal or above 15 % within the previous 60 days (value obtained at screening visit can be used for the value within the last 60 days) * participant must be on a stable highly active anti-retroviral treatment (haart) for 6 months (unless the change is due to tolerability, in which case the regimen can be for only the previous 3 months) and with an estimated adherence of ≥80% within the last 60 days. - a haart regimen (as defined by the argentinean art guidelines), means a combination of 2 nrtis plus one insti or a nnrti or a boosted pi or a dual combination of dolutegravir and 3tc. 3. able and willing (in the investigator's opinion) to comply with all study requirements. 4. willing to allow the investigators to discuss the volunteer's medical history with their general practitioner/personal doctor and access all medical records when relevant to study procedures. 5. healthy adults, or stable-healthy adults who may have a pre-existing medical condition that does not meet any exclusion criteria. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment. 6. for females of childbearing potential only, willingness to practice continuous effective contraception (see glossary) for 30 days prior to enrollment in the study, for 90 days after receiving vaccination during the study, and have a negative pregnancy test on the day(s) of screening/ vaccination (first injection visit and second injection visit). 7. males participating in this study who are involved in heterosexual sexual activity must agree to practice adequate contraception (see glossary) and refrain from donating sperm for 90 days after receiving the study vaccination. 8. agreement to refrain from blood donation during the study. 9. provide written informed consent.

inclusion criteria: adults of 18 years of age, and older. confirmed hiv infection at least two hiv plasma viral load (pvl) below 40 copies in the last 12 months, one within the last 60 days (value obtained at screening visit can be used for the value within the last 60 days) a cd4 count at screening equal or above 300 cells/ml and a cd4 percentage equal or above 15 % within the previous 60 days (value obtained at screening visit can be used for the value within the last 60 days) participant must be on a stable highly active anti-retroviral treatment (haart) for 6 months (unless the change is due to tolerability, in which case the regimen can be for only the previous 3 months) and with an estimated adherence of ≥80% within the last 60 days. - a haart regimen (as defined by the argentinean art guidelines), means a combination of 2 nrtis plus one insti or a nnrti or a boosted pi or a dual combination of dolutegravir and 3tc. able and willing (in the investigator's opinion) to comply with all study requirements. willing to allow the investigators to discuss the volunteer's medical history with their general practitioner/personal doctor and access all medical records when relevant to study procedures. healthy adults, or stable-healthy adults who may have a pre-existing medical condition that does not meet any exclusion criteria. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment. for females of childbearing potential only, willingness to practice continuous effective contraception (see glossary) for 30 days prior to enrollment in the study, for 90 days after receiving vaccination during the study, and have a negative pregnancy test on the day(s) of screening/ vaccination (first injection visit and second injection visit). males participating in this study who are involved in heterosexual sexual activity must agree to practice adequate contraception (see glossary) and refrain from donating sperm for 90 days after receiving the study vaccination. agreement to refrain from blood donation during the study. provide written informed consent.

inclusion criteria: adults of 18 years of age, and older. confirmed hiv infection at least two hiv plasma viral load (pvl) below 40 copies in the last 12 months, one within the last 60 days (value obtained at screening visit can be used for the value within the last 60 days) a cd4 count at screening equal or above 300 cells/ml and a cd4 percentage equal or above 15 % within the previous 60 days (value obtained at screening visit can be used for the value within the last 60 days) participant must be on a stable highly active anti-retroviral treatment (haart) for 6 months (unless the change is due to tolerability, in which case the regimen can be for only the previous 3 months) and with an estimated adherence of ≥80% within the last 60 days. - a haart regimen (as defined by the argentinean art guidelines), means a combination of 2 nrtis plus one insti or a nnrti or a boosted pi or a dual combination of dolutegravir and 3tc. able and willing (in the investigator's opinion) to comply with all study requirements. willing to allow the investigators to discuss the volunteer's medical history with their general practitioner/personal doctor and access all medical records when relevant to study procedures. healthy adults, or stable-healthy adults who may have a pre-existing medical condition that does not meet any exclusion criteria. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment. for females of childbearing potential only, willingness to practice continuous effective contraception (see glossary) for 30 days prior to enrollment in the study, for 90 days after receiving vaccination during the study, and have a negative pregnancy test on the day(s) of screening/ vaccination (first injection visit and second injection visit). males participating in this study who are involved in heterosexual sexual activity must agree to practice adequate contraception (see glossary) and refrain from donating sperm for 90 days after receiving the study vaccination. agreement to refrain from blood donation during the study. provide written informed consent.

inclusion criteria: 1. adults of 18 years of age, and older. 2. confirmed hiv infection - at least two hiv plasma viral load (pvl) below 40 copies in the last 12 months, one within the last 60 days (value obtained at screening visit can be used for the value within the last 60 days) - a cd4 count at screening equal or above 300 cells/ml and a cd4 percentage equal or above 15 % within the previous 60 days (value obtained at screening visit can be used for the value within the last 60 days) - participant must be on a stable highly active anti-retroviral treatment (haart) for 6 months (unless the change is due to tolerability, in which case the regimen can be for only the previous 3 months) and with an estimated adherence of ≥80% within the last 60 days. - a haart regimen (as defined by the argentinean art guidelines), means a combination of 2 nrtis plus one insti or a nnrti or a boosted pi or a dual combination of dolutegravir and 3tc. 3. able and willing (in the investigator's opinion) to comply with all study requirements. 4. willing to allow the investigators to discuss the volunteer's medical history with their general practitioner/personal doctor and access all medical records when relevant to study procedures. 5. healthy adults, or stable-healthy adults who may have a pre-existing medical condition that does not meet any exclusion criteria. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment. 6. for females of childbearing potential only, willingness to practice continuous effective contraception (see glossary) for 30 days prior to enrollment in the study, for 90 days after receiving vaccination during the study, and have a negative pregnancy test on the day(s) of screening/ vaccination (first injection visit and second injection visit). 7. males participating in this study who are involved in heterosexual sexual activity must agree to practice adequate contraception (see glossary) and refrain from donating sperm for 90 days after receiving the study vaccination. 8. agreement to refrain from blood donation during the study. 9. provide written informed consent.

inclusion criteria: 1. adults of 18 years of age, and older. 2. confirmed hiv infection - at least two hiv plasma viral load (pvl) below 40 copies in the last 12 months, one within the last 60 days (value obtained at screening visit can be used for the value within the last 60 days) - a cd4 count at screening equal or above 300 cells/ml and a cd4 percentage equal or above 15 % within the previous 60 days (value obtained at screening visit can be used for the value within the last 60 days) - participant must be on a stable highly active anti-retroviral treatment (haart) for 6 months (unless the change is due to tolerability, in which case the regimen can be for only the previous 3 months) and with an estimated adherence of ≥80% within the last 60 days. - a haart regimen (as defined by the argentinean art guidelines), means a combination of 2 nrtis plus one insti or a nnrti or a boosted pi or a dual combination of dolutegravir and 3tc. 3. able and willing (in the investigator's opinion) to comply with all study requirements. 4. willing to allow the investigators to discuss the volunteer's medical history with their general practitioner/personal doctor and access all medical records when relevant to study procedures. 5. healthy adults, or stable-healthy adults who may have a pre-existing medical condition that does not meet any exclusion criteria. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment. 6. for females of childbearing potential only, willingness to practice continuous effective contraception (see glossary) for 30 days prior to enrollment in the study, for 90 days after receiving vaccination during the study, and have a negative pregnancy test on the day(s) of screening/ vaccination (first injection visit and second injection visit). 7. males participating in this study who are involved in heterosexual sexual activity must agree to practice adequate contraception (see glossary) and refrain from donating sperm for 90 days after receiving the study vaccination. 8. agreement to refrain from blood donation during the study. 9. provide written informed consent.